Abstract
The binding of urokinase-type plasminogen activator (uPA) to its receptor (uPAR) on the surface of tumor cells is involved in the activation of proteolytic cascades responsible for the invasiveness of those cells. The diffuse, extensive infiltration of glioblastomas into the surrounding normal brain tissue is believed to rely on modifications of the proteolysis of extracellular matrix components; blocking the interaction between uPA and uPAR might be a suitable approach for inhibiting glioma tumorigenesis. We assessed how expression of an amino-terminal fragment (ATF) of uPA that contains binding site to uPAR affects the invasiveness of SNB19 human glioblastoma cells. SNB19 cells were transfected with an expression plasmid (pcDNA3-ATF) containing a cDNA sequence of ATF-uPA. The resulting ATF-uPA-expressing clones showed markedly less cell adhesion, spreading, and clonogenicity than did control cells. Endogenous ATF expression also significantly decreased the invasive capacity of transfected glioblastoma cells in Matrigel and spheroid-rat brain cell aggregate models. ATF-uPA transfectants were also markedly less invasive than parental SNB19 cells after injection into the brains of nude mice, suggesting that competitive inhibition of the uPA-uPAR interaction on SNB19 cells by means of transfection with ATF cDNA could be a useful therapeutic strategy for inhibiting tumor progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andreasen PA, Kjoller L, Christensen L, Duffy MJ . 1997 Int. J. Cancer 72: 1–22
Burgle M, Koppitz M, Riemer C, Kessler H, Konig B, Weidle UH, Kellermann J, Lottspeich F, Graeff H, Schmitt M, Goretzki L, Reuning U, Wilhelm O, Magdolen V . 1997 J. Biol. Chem. 378: 231–237
Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD . 1993 Proc. Natl. Acad. Sci. USA. 90: 5021–5025
Dear AE, Medcalf RL . 1998 Eur. J. Biochem. 252: 185–193
Duffy MJ . 1996 Clin. Cancer Res. 2: 613–618
Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M . 1998 Clin. Exp. Metastasis 16: 513–528
Go Y, Chintala SK, Mohanam S, Gokaslan Z, Venkaiah B, Bjerkvig R, Oka K, Nicolson GL, Sawaya R, Rao JS . 1997 Clin. Exp. Metastasis 15: 440–446
Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa N, Terao T . 1994 Int. J. Cancer 57: 727–733
Kruger A, Soeltl R, Lutz V, Wilhelm OG, Magdolen V, Rojo EE, Hantzopoulos PA, Graeff H, Gansbacher B, Schmitt M . 2000 Cancer Gene Ther. 7: 292–299
Li H, Lu H, Griscelli F, Opolon P, Sun LQ, Ragot T, Legrand Y, Belin D, Soria J, Soria C, Perricaudet M, Yeh P . 1998 Gene. Ther. 5: 1105–1113
Luparello C, Del Rosso M . 1996 Eur. J. Cancer 32A: 702–707
Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S . 1996 Cancer Res. 56: 2428–2433
Mohanam S, Chintala SK, Go Y, Bhattacharya A, Venkaiah B, Boyd D, Gokaslan ZL, Sawaya R, Rao JS . 1997 Oncogene 14: 1351–1359
Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Kin Y, Fuller GN, Lakka SS, Kyritsis AP, Dinh DH, Olivero WC, Gujrati M, Yung WK, Rao JS . 2001 Clin. Cancer Res. 7: 2519–2526
Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, Rao JS . 1993 Cancer Res. 53: 4143–4147
Quax PH, Grimbergen JM, Lansink M, Bakker AH, Blatter MC, Belin D, van Hinsbergh VW, Verheijen JH . 1998 Arterioscler. Thromb. Vasc. Biol. 18: 693–701
Quax PH, Lamfers ML, Lardenoye JH, Grimbergen JM, de Vries MR, Slomp J, de Ruiter MC, Kockx MM, Verheijen JH, van Hinsbergh VW . 2001 Circulation 103: 562–569
Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J, Goltzman D . 1992 J. Biol. Chem. 267: 14151–14156
Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M . 1998 Int. J. Oncol. 13: 893–906
Schmitt M, Wilhelm OG, Reuning U, Kruger A, Harbeck N, Lengyel E, Graeff H, Gansbacher B, Kessler H, Burgle M, Sturzebecher J, Sperl S, Magdolen V . 2000 Fibrinol. Proteol. 14: 114–132
Stahl A, Mueller BM . 1997 Int. J. Cancer 71: 116–122
Waltz DA, Fujita RM, Yang X, Natkin L, Zhuo S, Gerard CJ, Rosenberg S, Chapman HA . 2000 Am. J. Respir. Cell Mol. Biol. 22: 316–322
Yamamoto M, Sawaya R, Mohanam S, Bindal AK, Bruner JM, Oka K, Rao VH, Tomonaga M, Nicolson GL, Rao JS . 1994a Cancer Res. 54: 3656–3661
Yamamoto M, Sawaya R, Mohanam S, Rao VH, Bruner JM, Nicolson GL, Rao JS . 1994b Cancer Res. 54: 5016–5020
Zhu F, Jia S, Xing G, Gao L, Zhang L, He F . 2001 DNA Cell Biol. 20: 297–305
Acknowledgements
We thank Karen Minter for preparing the manuscript. This work was supported by National Cancer Institute grants CA76350, CA75557 and CA85216 (to JS Rao).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mohanam, S., Chandrasekar, N., Yanamandra, N. et al. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Oncogene 21, 7824–7830 (2002). https://doi.org/10.1038/sj.onc.1205893
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205893
Keywords
This article is cited by
-
Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase
Molecular Cancer (2013)
-
Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain
Laboratory Investigation (2005)
-
RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas
Oncogene (2004)
-
Molecular mechanisms of glioma invasiveness: the role of proteases
Nature Reviews Cancer (2003)